RE:RE:RE:RE:RE:RE:ViiV Presentation in London - fostemsavirI wrote this a while ago:
Lots to digest.
A few comments after a quick review.
(1) Viiv was very brief in their discussion of meeting their primary endpoint. That makes me think they were not particularly impressed with the results
(2)Fostemsavir led to 64% having > 0.5 log reduction in HIV RNA at Day 8. Trogarzo achieved that target in 83%. Were Trogarzo patients also sicker at baseline?
(3)Trogarzo achieved mean viral load reduction at 24 weeks of 3.1 log. Fostemsavir was 2.29 log and did not get better even at 48 weeks.
(4) Most patients that received Fostemsavir had at least one adverse event. It seems like Trogarzo is likely better tolerated.
Anyway, I guess we can’t see what proportion of patients in this study were on Trogarzo as well.
I don’t think I see a big threat especially given Trogarzo’s head start.
bfw
Read more at https://www.stockhouse.com/companies/bullboard/t.th/theratechnologies-inc?postid=28911569#FCytOHYlWTS8zpsL.99